DDInter493 DDInter1376
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Degarelix {u} (Compound) resembles {v} (Compound) Nafarelin
Degarelix {u} (Compound) resembles {v} (Compound) Cetrorelix
Degarelix {u} (Compound) treats {v} (Disease) prostate cancer
Degarelix {u} (Compound) binds {v} (Gene) GNRHR
Degarelix {u} (Compound) causes {v} (Side Effect) Urticaria
Degarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Degarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Degarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Degarelix {u} may lead to a major life threatening interaction when taken with {v} Amiodarone
Degarelix {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Degarelix (Compound) resembles Nafarelin (Compound)
Degarelix (Compound) resembles Cetrorelix (Compound)
Degarelix (Compound) treats prostate cancer (Disease)
Degarelix (Compound) binds GNRHR (Gene)
Degarelix (Compound) causes Urticaria (Side Effect)
Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Degarelix may lead to a major life threatening interaction when taken with Amiodarone
Degarelix may lead to a major life threatening interaction when taken with Ivabradine